ChinaBio® Today Blog | Talkmarkets | Page 1
News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

All Contributions

Latest Posts
1 to 16 of 290 Posts
1 2 3 ... 19
Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO
Zai Lab​ of Shanghai is conducting a Hong Kong IPO that is expected to raise up to $845 million, offering 12.3% of the company's expanded number of shares. On the Nasdaq Exchange, Zai has a market capitalization of $6.2 billion.
Week In Review: Baidu Raising $2 Billion For New China Biopharma
Baidu, one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company. It believes the $2 billion fundraising will take two years to complete.
Week In Review: I-Mab Partners CD47 With AbbVie In $2 Billion Deal
I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement. AbbVie also acquired right-of-first-refusal to two other CD47 molecules, which would each trigger a $500 million payment.
Week In Review: Antengene Approved By Hong Kong Exchange For $200 Million IPO
Antengene, a three-year old Shanghai startup originally backed by Celgene, will conduct a Hong Kong IPO that is expected to raise $200 million. BeiGene acquired China rights to Bio-Thera's Avastin® biosimilar in an agreement worth up to $165 million.
Week In Review: Innovent Out-Licenses Ex-China Rights For PD-1 To Lilly In $1 Billion Deal
Suzhou Innovent Bio expanded its 2015 alliance with Eli Lilly for Tyvyt®, Innovent's anti-PD-1 immunotherapy. In return for a $1+ billion package, Lilly will have an exclusive license to develop Tyvyt in ex-China markets.
Week In Review: $2.5 Billion In Deals Including LianBio's Initial $719 Million In In-Licensings
LianBio, a new Princeton-Shanghai company, acquired China rights to two BridgeBio oncology assets in a $531.5 million agreement. BridgeBio will receive $26.5 million in upfront payments, plus up to $505 million in future milestones.
Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture, and market AstraZeneca's COVID-19 vaccine in China. Biogen announced a $2 billion deal to partner Denali Therapeutics' potential Parkinson's Disease therapy.
Week In Review: Shanghai Hansoh Enters $68 Million Deal For Leukemia Candidate
Shanghai Hansoh Pharma obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment, plus milestones of up to $68 million. It will also pay royalties on sales.
Week In Review: BeiGene Signs $540 Million Deal For China Rights To Three HBV Candidates
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Bio in a $540 million agreement. BeiGene, which will make a $40 million upfront payment, is responsible for $500 million in milestones.
Week In Review: China Life Science Announces $5 Billion In Deals, A Weekly Record
BeiGene, a Beijing oncology drug biopharma, announced a $2.1 billion private placement that will bring its cash holdings to almost $5.5 billion The company is developing a portfolio of 25 candidates, with several of them in Phase III tests.
Week In Review: Ocumension Climbs To $2.5 Billion Market Cap After $184 Million Hong Kong IPO
Ocumension, a Shanghai ophthalmic pharma, completed a $184 million Hong Kong IPO and climbed 152% in its first trading session, giving the company a valuation of about $2.5 billion. The company has raised $200 million in venture capital.
Week In Review: China Life Science Announces Deals Worth $1.3 Billion
Boehringer Ingelheim launched its External Innovation Hub China in Shanghai to increase the company's China R&D partnerships.. The Hub has $508 million to spend on China clinical research, expansion of production sites and research partnerships.
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement.
Week In Review: Six China Biopharma Deals Raise A Total Of $255 Million
Immvira Group, a Shenzhen biotech developing oncolytic virus therapies, completed a $58 million Series B financing. Miaoshou Doctor, an online-offline healthcare company headquartered in Beijing, closed an $85 million Series D1 round.
Week In Review: Suzhou Innovent Announces $2 Billion Immunotherapy Collaboration With Roche
Suzhou Innovent Bio formed a far-reaching R&D collaboration with Roche that has a potential value of over $2 billion. Roche will have an option to license each product for ex-China development and commercialization.
Week In Review: China Life Science Companies Raise Nearly $1 Billion Led By Legend's $424 Million US IPO
In a successful debut offering, Nanjing Legend Biotech priced its US IPO above the expected range at $23 per ADS, raising $424 million. The company's ADS's climbed 60% higher to $36.60, giving Legend a market capitalization of nearly $5 billion.
1 to 16 of 290 Posts
1 2 3 ... 19